# Agent run trace — `run-eval-t2d_treatment_options`

**Question:** What are the latest treatment options for Type 2 diabetes?

- Model: `nvidia/nemotron-3.5-lightning-30b-a3b`
- LLM mode: `record` · PubMed mode: `record`

---

## 1. Input guardrail _(0 ms)_

- **chars**: 58
- **allowed**: true
- **reason**: passed all input checks

## 2. Planner _(11403 ms)_

- **interpretation**: The user seeks current pharmacological treatment options for adults with type 2 diabetes mellitus, emphasizing recently introduced agents and how they are positioned in contemporary clinical guidelines.
- **sub_questions**: ["What are the first-line and second-line glucose-lowering drug recommendations for adults with type 2 diabetes per current guidelines?", "What efficacy and safety data support the use of newer incretin-based agents (tirzepatide, semaglutide) as treatment options for type 2 diabetes?", "How do SGLT2 inhibitors and GLP-1 receptor agonists affect cardiovascular and renal outcomes in adults with type 2 diabetes?"]
- **mesh_terms**: ["Diabetes Mellitus, Type 2", "Hypoglycemic Agents", "Sodium-Glucose Transporter 2 Inhibitors", "Glucagon-Like Peptide-1 Receptor Agonists"]
- **searches**: ["Diabetes Mellitus, Type 2", "('tirzepatide'[All Fields] OR 'semaglutide'[All Fields]) AND 'Diabetes Mellitus, Type 2'[MeSH Terms]", "('Sodium-Glucose Transporter 2 Inhibitors'[MeSH Terms] OR 'Glucagon-Like Peptide-1 Receptor Agonists'[MeSH Terms]) AND ('cardiovascular outcomes'[All Fields] OR 'Kidney Diseases'[MeSH Terms])"]

## 3. Researcher _(915 ms)_

- **iteration**: 1
- **wants_tool**: true
- **tools**: ["pubmed_search"]

## 4. Tool call _(1341 ms)_

- **tool**: pubmed_search
- **arguments**: {"date_from": 2021, "pub_types": ["Practice Guideline", "Systematic Review"], "max_results": 20, "query": "Diabetes Mellitus, Type 2[MeSH Terms]"}
- **result_summary**: {"executed_query": "(Diabetes Mellitus, Type 2[MeSH Terms]) AND (\"Practice Guideline\"[Publication Type] OR \"Systematic Review\"[Publication Type]) AND (\"2021\"[Date - Publication] : \"3000\"[Date - Publication])", "total_matches": 3311, "returned": 12, "results": "[12 items]", "note": "Abstracts are retained for synthesis; no further fetch is required."}

## 5. Researcher _(1747 ms)_

- **iteration**: 2
- **wants_tool**: true
- **tools**: ["pubmed_search"]

## 6. Tool call _(678 ms)_

- **tool**: pubmed_search
- **arguments**: {"query": "(tirzepatide OR semaglutide) AND Diabetes Mellitus, Type 2[MeSH Terms]", "date_from": 2022, "max_results": 20, "pub_types": ["Randomized Controlled Trial"]}
- **result_summary**: {"executed_query": "((tirzepatide OR semaglutide) AND Diabetes Mellitus, Type 2[MeSH Terms]) AND (\"Randomized Controlled Trial\"[Publication Type]) AND (\"2022\"[Date - Publication] : \"3000\"[Date - Publication])", "total_matches": 190, "returned": 12, "results": "[12 items]", "note": "Abstracts are retained for synthesis; no further fetch is required."}

## 7. Researcher _(937 ms)_

- **iteration**: 3
- **wants_tool**: true
- **tools**: ["pubmed_search"]

## 8. Tool call _(774 ms)_

- **tool**: pubmed_search
- **arguments**: {"query": "(Sodium-Glucose Transporter 2 Inhibitors[MeSH Terms] OR Glucagon-Like Peptide-1 Receptor Agonists[MeSH Terms]) AND (cardiovascular outcomes[All Fields] OR Kidney Diseases[MeSH Terms])", "date_from": 2020, "max_results": 20, "pub_types": ["Meta-Analysis", "Randomized Controlled Trial"]}
- **result_summary**: {"executed_query": "((Sodium-Glucose Transporter 2 Inhibitors[MeSH Terms] OR Glucagon-Like Peptide-1 Receptor Agonists[MeSH Terms]) AND (cardiovascular outcomes[All Fields] OR Kidney Diseases[MeSH Terms])) AND (\"Meta-Ana…", "total_matches": 498, "returned": 12, "results": "[12 items]", "note": "Abstracts are retained for synthesis; no further fetch is required."}

## 9. Researcher _(7950 ms)_

- **iteration**: 4
- **wants_tool**: false
- **text**: **Summary of evidence retrieved**

### 1. First‑line and second‑line glucose‑lowering drug recommendations (current guidelines)

- **AACE 2022 guideline** (PMID 35963508) and the **AACE 2026 algorithm** (PMID 41842862) position metformin as the universal first‑line agent, with subsequent therapy ind

## 10. Ranking (RAG) _(1390 ms)_

- **candidates**: 32
- **method**: embedding_cosine
- **selected**: ["41842862", "38639546", "41203232", "39675348", "40156846", "38852020", "40975112", "40156843"]

## 11. Synthesizer _(12780 ms)_

- **evidence_count**: 8
- **claims**: 3
- **grade**: moderate
- **summary**: For most adults with type 2 diabetes, current guidelines recommend adding a sodium‑glucose cotransporter‑2 (SGLT2) inhibitor or a glucagon‑like peptide‑1 (GLP‑1) agonist to metformin and lifestyle changes, based on high‑certainty evidence of cardiovascular and renal benefits (PMID 38639546). In addi

## 12. Critic _(13851 ms)_

- **claims**: 3
- **verdict**: accept
- **reasoning**: All three claims are grounded in the cited abstracts. Claim 1 correctly reflects the ACP guideline's strong recommendation with high‑certainty evidence for adding an SGLT2 inhibitor or GLP‑1 agonist to metformin and lifestyle. Claim 2 accurately summarizes the meta‑analysis of long‑acting GLP‑1RA ou

## 13. Output guardrail _(0 ms)_

- **claims_kept**: 3
- **claims_dropped**: 0
- **citation_rate**: 1.0

## 14. Final answer

- **claims**: 3
- **citations**: 3
- **grade**: moderate
- **citation_rate**: 1.0
- **degraded**: false

## 15. Run complete

- **run_id**: eval-t2d_treatment_options
- **events**: 53
- **llm_requests**: 9
- **tool_calls**: 3
- **retries**: 0
- **elapsed_seconds**: 53.93
- **trace_path**: /home/user/agent/traces/run-eval-t2d_treatment_options.jsonl
- **prompt_tokens**: 27739
- **output_tokens**: 11097
- **thoughts_tokens**: 0
